EFFECTOR Therapeutics to Collaborate with the Dana-Farber Ca

EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 -- eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,...

Related Keywords

United States , Panagiotis Konstantinopoulos , Michael Fitzhugh , Christopherm Calabrese , Kevin Gardner , Doug Warner , Lifesci Communications , Nasdaq , Professor Of Medicine At Harvard Medical School , Dana Farber Cancer Institute , Exchange Commission , Pfizer , Effector Therapeutics Inc , Translational Research , Division Of Gynecologic Oncology , Gynecologic Oncology , Associate Professor , Harvard Medical , Private Securities Litigation Reform Act ,